Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

SOHO State of the Art Updates and Next Questions | Progress in Higher-Risk Myelodysplastic Syndromes.

Clinical lymphoma, myeloma & leukemia·2026

Same author

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Blood cancer journal·2026

Same author

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

HemaSphere·2026

Same author

Promoter TERT-Related Hematopoietic Somatic Mosaicism in Patients With Telomere Biology Disorders.

American journal of hematology·2026

Same author

Evolution to complex karyotype disease in mono-allelic <i>TP53</i>-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort study.

Haematologica·2026

Same author

PT/Cy-based alloBMT platform as a curative, accessible alternative for pediatric and young adult severe aplastic anemia.

Blood advances·2026

Search research articles

Related Experiment Video

Updated: Jun 27, 2025

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

Modified Delphi panel consensus recommendations for management of severe aplastic anemia.

Daria V Babushok¹, Amy E DeZern², Carlos M de Castro³

¹Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA.

|April 26, 2024

Summary

This study provides expert consensus recommendations for managing severe aplastic anemia (SAA). The guidelines cover initial and subsequent treatments, focusing on transplant versus medical therapy for acquired SAA.

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

Related Experiment Videos

Last Updated: Jun 27, 2025

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

Area of Science:

Hematology
Oncology
Clinical Medicine

Background:

Severe aplastic anemia (SAA) is a rare hematologic disorder lacking a definitive management algorithm.
Current treatment strategies for SAA require clear guidelines to optimize patient outcomes.

Purpose of the Study:

To develop evidence-based clinical recommendations for the management of severe aplastic anemia (SAA) across all age groups.
To provide guidance on initial and subsequent therapy, including distinguishing between transplant and medical interventions.

Main Methods:

A modified Delphi panel method was employed, involving 11 experts in adult and pediatric aplastic anemia.
Over 600 patient care scenarios were evaluated to establish consensus-based recommendations.

Main Results:

Recommendations were formulated for ruling out inherited bone marrow failure syndromes.
Guidelines address supportive care before and during first-line therapy for acquired SAA.
Consensus was reached on first-line and second-line treatment strategies, including the optimal timing for stem cell transplant versus medical therapy.

Conclusions:

The expert panel's recommendations offer guidance for experienced clinicians treating SAA patients.
Validation of these consensus guidelines through clinical data is recommended to improve SAA patient outcomes.
These recommendations aim to standardize and enhance the care of individuals diagnosed with severe aplastic anemia.